Phase 2 study of AGN-151607 epicardial fat pad injections to prevent post-operative atrial fibrillation after open-chest cardiac surgery

Phase 2, randomised, double-blind trial of neuronox in Atrial fibrillation (AFib) (3 arms), sponsored by Allergan. Primary endpoint: Percentage of participants with at least 1 continuous atrial fibrillation episode for at least 30 seconds during the first 30 days post-surgery. Planned start Jan 2019; status: withdrawn.